Adult soft tissue myoepithelial carcinoma: Treatment outcomes and efficacy of chemotherapy

Impending Doom: A Rare Case of Metastatic Myoepithelial Carcinoma

“…It is advised that myoepithelial neoplasms are best examined with a tumor panel that includes all antibodies to broad-spectrum keratins, high-molecular-weight keratins, and myofilaments [6]. About 95% of tumors express reactivity to keratin (CKAE 1/3), S100, EMA, PAN-K, CAM 5.2, pan-cytokeratin, calponin, SMA, muscle-specific actin (MSA), smooth muscle myosin, P63 protein, glial fibrillary acidic protein (GFAP), CD10, desmin, and p63 [2][3][4][5][6][7][8][9][10][11][12][13][14][15][16][17]. In our case, the tumor was immunoreactive to SOX-10, CKAE 1/3, CAM 5.2, BCL-2, vimentin, and S100 confirming the diagnosis of myoepithelial carcinoma.…”

“…At present, there is no consensus evidence-based treatment modality for this neoplasm particularly due to its rarity. However, in a large single-center retrospective study described by Chamberlain et al, the recommendation for primary treatment of localized disease was complete surgical resection with or without radiation therapy [14]. Neoadjuvant radiation therapy to debulk the tumor can be considered in certain groups of patients at risk of significant tissue/limb loss.…”

“…Given the rarity of this malignancy, the clinical course and treatment modalities remain undefined. Multiple treatment modalities have been described in case reports, ranging from complete surgical resection with clear margins to chemotherapy and/or neoadjuvant /adjuvant radiotherapy [3][4][5][6][7][8][9][10][11][12][13][14][15][16]. There are limited reports of deep soft tissue myoepithelial carcinoma with concurrent metastasis and rapid mortality [10][11][12][13].…”

Anti-androgen for myoepithelial tumor: a potent therapy yet a potential misleader

“…Due to its rarity, there is a paucity of data regarding molecular profiling and treatment paradigm. Various cytotoxic agents have been used for treating metastatic disease with up to two-thirds of patients achieving stable disease at best [6]. Partial responses are uncommon and no complete responses have been reported.…”

“…Partial responses are uncommon and no complete responses have been reported. Patient's outcomes are generally poor with 5-years overall survival (OS) being around 15% and median progression-free survival (PFS) of approximately 9 months [6].…”